Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $11.09 Average Price Target from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $11.0909.

Several equities research analysts have weighed in on TSHA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Wells Fargo & Company upped their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, UBS Group set a $11.00 target price on Taysha Gene Therapies in a research note on Thursday, December 4th.

Insiders Place Their Bets

In other news, insider Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $124,091.98. Following the sale, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. This trade represents a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP raised its holdings in Taysha Gene Therapies by 150.0% in the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock worth $75,625,000 after purchasing an additional 8,250,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Taysha Gene Therapies by 2.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock valued at $75,310,000 after purchasing an additional 309,031 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Taysha Gene Therapies by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after purchasing an additional 418,192 shares in the last quarter. Octagon Capital Advisors LP increased its position in shares of Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after buying an additional 1,892,500 shares during the period. Finally, State Street Corp increased its position in shares of Taysha Gene Therapies by 49.1% during the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after buying an additional 3,553,619 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $4.53 on Friday. The company has a market capitalization of $1.30 billion, a P/E ratio of -13.33 and a beta of 1.02. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a 50 day moving average price of $4.63 and a two-hundred day moving average price of $4.58.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 56.64%. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $1.89 million. Analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.